According to Zacks, analysts expect that EXACT Sciences will report full year earnings of ($0.84) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.54). However the low revenue estimates for the company are $84.6 Million versus high revenue estimates of $93.92 Million.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.09.

The Company now has ROA (Return on Assets) of 4.5 percent, Return on Equity (ROE) of 9.8 Percent and Return on Investment (ROI) of 1% with Gross margin of 53 percent and Operating & Profit margin of -9.8% and 32.3% respectively. The company's past year sales total was 48360. During the same period previous year, the firm posted ($0.34) earnings per share. BidaskClub upgraded EXACT Sciences from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 7th. Benchmark set a $65.00 price target on shares of EXACT Sciences and gave the company a "buy" rating in a report on Wednesday, January 17th.

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. EXACT Sciences presently has a consensus rating of "Buy" and an average target price of $52.84.

Exact Sciences Corporation (EXAS) added 2.5% to reach $52.15 in the previous trading session. Its share price has decline -2.94% in three months and is up 14.82% for the last five trades. EXACT Sciences has a 12-month low of $19.91 and a 12-month high of $63.60. The firm has a market capitalization of $6,307.13, a price-to-earnings ratio of -52.15 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.77 and a current ratio of 7.15.

In related news, insider Graham Peter Lidgard sold 39,884 shares of the firm's stock in a transaction dated Wednesday, February 28th. About 4.05 million shares traded or 42.18% up from the average. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. On Friday, February 23 COWARD D SCOTT sold $187,134 worth of Exact Sciences Corporation (NASDAQ:EXAS) or 4,420 shares. The stock was sold at an average price of $42.34, for a total transaction of $522,983.68. Following the sale, the insider now owns 955,454 shares in the company, valued at approximately $50,438,416.66. The disclosure for this sale can be found here.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Zweig holds 1.82% in Exact Sciences Corporation (NASDAQ:EXAS) or 430,841 shares. Riverhead Capital Management Ltd Com holds 33,800 shares. Dimensional Fund Advisors LP acquired a new stake in EXACT Sciences in the 2nd quarter worth approximately $3,939,000. Following the sale, the senior vice president now directly owns 37,558 shares in the company, valued at $1,973,297.32. It also increased its holding in Lendingtree Inc New Com (NASDAQ:TREE) by 16,047 shares in the quarter, for a total of 16,089 shares, and has risen its stake in Control4 Corp Com (NASDAQ:CTRL). Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company's stock worth $62,499,000 after purchasing an additional 539,160 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of EXACT Sciences by 95.8% in the 3rd quarter. Investors who are keeping close eye on the stock of Kohl's Corporation (NYSE:KSS) established that the company was able to keep return on investment at 6.79 in the trailing twelve month while Reuters data showed that industry's average stands at 12.86 and sector's optimum level is -36.39. Finally, Emerald Advisers Inc. Green Valley Investors LLC owned 0.77% of EXACT Sciences worth $48,531,000 at the end of the most recent quarter. Institutional investors own 81.10% of the company's stock.

WARNING: This piece of content was reported by BBNS and is owned by of BBNS.

COPYRIGHT VIOLATION NOTICE: "EXACT Sciences (NASDAQ:EXAS) PT Set at $67.00 by Leerink Swann" was originally reported by Enterprise Leader and is the property of of Enterprise Leader. EXACT Sciences had 69 analyst reports since July 24, 2015 according to SRatingsIntel.

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Sells 6234 Shares of Celgene Co. (CELG)
The firm has a market capitalization of $69,410.00, a price-to-earnings ratio of 17.58, a P/E/G ratio of 0.65 and a beta of 1.58. News headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive recently, according to Accern Sentiment.

USA stocks rise ahead of inflation, retail sales data
Retail Sales are expected to make a recovery from last month's disappointing -0.3% performance with a reading of 0.3%. The deal values Oclaro at $9.99 a share, or $1.69 billion, and its stock gained $2.10, or 26.7 percent, to $9.95.

Unions block Eskom signing renewable energy deals
We are confident that the court will recognize that our rights have been violated and will look favorably on our application. The combination of all these factors will have dire consequences for the working class and the poor .